Version: 1.0.0 | Published: 31 Aug 2026 | Updated: 8 days ago
Documentation
Description:
Multiple myeloma is a type of bone marrow cancer, making up about 2% (6,000) of all new cancer cases in the UK each year. A common treatment for myeloma is an autologous stem cell transplant (ASCT), where high doses of chemotherapy are used to destroy as many cancer cells as possible. Then, stem cells (early-stage cells that can develop into different types of blood cells) are put back into the patient"s body to help bone marrow make new, healthy blood cells. At the Royal Marsden Hospital, we perform around 100 transplants for myeloma patients annually. However, this treatment can cause significant side effects and affect the quality of life for several months.
Myeloma patients often experience a high number of symptoms and a lower quality of life, which can vary greatly from person to person.
Gauging fitness and activity levels helps inform whether a patient is fit enough for treatment and predict how the treatment might affect then.
This study aimed to find out if using wearable devices is a practical way to track specific aspects of activity (including total daily steps, distance walked, heart rate, sleep patterns, blood oxygen levels, and skin temperature), before, during, and after ASCT - and to see if these activity levels correlate with other measures of patient well-being.
Coverage
Spatial:
Sutton LB, United Kingdom
Typical Age Range:
18-150
Follow Up:
Other
Pathway:
The dataset represents a defined segment of the multiple myeloma patient
pathway: the peri-autologous stem cell transplantation period at a single
specialist tertiary cancer centre. Participants were followed from approximately
10 days before transplant until 28 days after stem cell infusion, spanning
pre-transplant assessment, transplantation, inpatient or ambulatory care, and
early post-transplant recovery. During this period, wearable devices captured
measures including daily step count, distance walked, heart rate, sleep, blood
oxygen and skin temperature. Patient-reported outcome measures were also
collected at baseline and Day +28. The dataset includes patients managed through
both ambulatory and inpatient autologous stem cell transplant pathways, enabling
comparison across these two care settings. The dataset does not represent the
complete multiple myeloma pathway. It does not include longitudinal data from
diagnosis, induction treatment, later post-transplant recovery, maintenance
therapy, relapse, or subsequent lines of treatment. It is also limited to care
delivered within a single specialist haemato-oncology service and is not linked
across primary, secondary and community care. Findings should therefore be
interpreted as representing the early peri-transplant and recovery phase rather
than the full patient journey.
Provenance
Origin
Purposes:
Study
Sources:
- EPR
- Machine generated
- Paper-based
- Other
Collection Situations:
Cohort, study, trial
Temporal
Accrual Periodicity:
Static
Start Date:
22 July 2024
End Date:
30 October 2025
Time Lag:
Not applicable
Accessibility
Access
Access Rights:
in progress
Access Service:
Although not required, there is an option to use The Royal Marsden’s Trusted
Research Environment and informatics platform: BRIDgE (Biomedical Research
Informatics Digital Environment). BRIDgE is managed by The Royal Marsden’s
Information Team with support by the NIHR Biomedical Research Centre at The
Royal Marsden and ICR. The aim of the platform is to transform clinical practice
and improve outcomes for patients by enabling researchers to access real-world
cancer data within secure, collaborative, cloud-based workspaces. Learn more by
visiting the BRIDgE site within the NIHR BRC area of The Royal Marsden and ICR
website: https://www.cancerbrc.org/BRIDgE
Access Request Cost:
Depends on type of access. Costing available on application.
Delivery Lead Time:
Variable
Jurisdictions:
UK
Data Controller:
Royal Marsden NHS Foundation Trust
Data Processor:
Royal Marsden NHS Foundation Trust
Usage
Data Use Limitations:
Research-specific restrictions
Data Use Requirements:
- Ethics approval required
- Institution-specific restrictions
- Not for profit use
- User-specific restriction
Resource Creators:
The Royal Marsden NHS Foundation Trust; The Royal Marsden Cancer Charity; NIHR Biomedical Research Centre at The Royal Marsden and the ICR
Format and Standards
Vocabulary Encoding Schemes:
LOCAL
Conforms To:
LOCAL
Languages:
en